Semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Under the influence of estrogen, stromal and fat tissue surrounding the ductal system in the mammary glands also grows. After puberty, GH and IGF-1 levels progressively decrease, which limits further development until pregnancy, if it occurs. During pregnancy, progesterone and prolactin are essential for mediating lobuloalveolar development in estrogen-primed mammary gland tissue, which occurs in preparation of lactation and nursing. Androgens such as testosterone inhibit estrogen-mediated mammary gland development (e.g., by reducing local ER expression) through activation of androgen receptors expressed in mammary gland tissue, and in conjunction with relatively low estrogen levels, are the cause of the lack of developed mammary glands in males.
=== India and Nepal === Sickle cell disease is common in some ethnic groups of central India, where the prevalence has ranged from 9.4 to 22.2% in endemic areas of Madhya Pradesh, Rajasthan, and Chhattisgarh. It is also endemic among Tharu people of Nepal and India; however, they have a sevenfold lower rate of malaria despite living in a malaria infested zone.
Machamer (1964), philosopher and historian of science; professor at the University of Pittsburgh Mike Wallace (1964), historian and winner of the 1999 Pulitzer Prize for History for Gotham: A History of New York City to 1898 Jonathan Goldberg (1964), professor at Emory University Michael M. Gunter (1964), professor at Tennessee Technological University, authority in Kurdish studies Miles Orvell (1964), professor at Temple University, former editor of the Encyclopedia of American Studies Jonathan M. Weiss (1964), scholar of French literature and politics George R. Goldner (1965), former curator at the Metropolitan Museum of Art J. Bruce Jacobs (1965), Australian orientalist who specialized in Taiwan studies, professor at Monash University Richard Kagan (1965), historian, professor of Spanish history at Johns Hopkins University Richard Taruskin (1965), musicologist Walter Reich (1965), former director of United States Holocaust Memorial Museum and professor at George Washington University Mark Steiner (1965), professor of philosophy at the Hebrew University of Jerusalem Raymond Geuss (1966), specialist in Jürgen Habermas Steven Handel (1966), restoration ecologist, professor at Rutgers University Michael Hechter (1966), professor of political science at Arizona State University Ira Katznelson (1966), political scientist and historian, professor at Columbia University Mark D. Naison (1966), former political activist; professor of history at Fordham University T. J.
Sources: en.wikipedia.org
Though no Tyrannosaurus scleral ring has been found, Kenneth Carpenter estimated its size based on that of Gorgosaurus. The inferred scleral ring for the Stan specimen is ~7 cm (2.8 in) in diameter with an internal aperture diameter of ~3.5 cm (1.4 in). Based on eye proportions in living reptiles, this implies a pupil diameter of about 2.5 cm (0.98 in), an iris diameter about that of the scleral ring, and an eyeball diameter of 11–12 cm (4.3–4.7 in). Carpenter also estimated an eyeball depth of ~7.7–9.6 cm (3.0–3.8 in). Based on these calculations, the f-number for Stan's eye is 3–3.8; since diurnal animals have f-numbers of 2.1 or higher, this would indicate that Tyrannosaurus had poor low-light vision and hunted during the day. Tyrannosaurus had very large olfactory bulbs and olfactory nerves relative to their brain size, the organs responsible for a heightened sense of smell. This suggests that the sense of smell was highly developed, and implies that tyrannosaurs could detect carcasses by scent alone across great distances. The sense of smell in tyrannosaurs may have been comparable to modern vultures, which use scent to track carcasses for scavenging. Research on the olfactory bulbs has shown that T. rex had the most highly developed sense of smell of 21 sampled non-avian dinosaur species.
== Model systems == Human models for cystinosin are typically derived from cystinotic renal tubular cell lines. Non-human protein homologs for cystinosin include ERS1 in Saccharomyces cerevisiae (yeast cells) and the Caenorhabditis elegans protein, C41C4.7. Murine ctns has also been used.
In the present, she is shown to have a healthy work/life balance and uses her position to help avoid layoffs. Kendra has a younger brother named David. Max Greenfield as Yoshi Schwooper, the youngest of the Schwooper children, and second son of Naomi and Elliot. Born in 1991, he is lackadaisical and somewhat socially awkward, but kind and laid-back. As a teenager he was diagnosed with ADHD, dyslexia, and executive dysfunction, all of which cause him difficulties with managing a career in his adulthood. In 2014-2015 Yoshi interns on a farm in Vermont. By 2019, Yoshi starts practicing modern Orthodox Judaism, which helps him to find stability. Yoshi, since infancy, has tried to connect and spend time with his siblings. However, being seven years younger, he feels like an extra child. Lisa Edelstein as Naomi Schwartz, the matriarch of the Schwooper family, and mother of Avi, Shira and Yoshi. Born in 1952, Naomi is the youngest of three daughters; they all grew up in a cramped New York apartment along with their parents. She is very self-centered and has a tendency to gain attention from her family by manipulating them. While Naomi loves her children, she is overbearing and critical, and her behavior has a deep effect on them. In 2019, her children confront Naomi about her controlling actions toward them. Naomi once worked as a social worker; to Avi's surprise, during a ceremony for her, it is revealed that Naomi has helped many people in the community, being more open-minded and supportive to strangers than her own children. In 2020, Naomi dies after contracting COVID-19.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.